hat’s a good use of $64 billion? Is Big Biotech boring now? And what’s the best way to sell hair restoration products to men?
We discuss all that and at least a little more on the latest episode of “The Readout LOUD,” STAT’s biotech podcast. Stick around for a parsing of the potential Takeda-Shire merger, a dive into the benefits and risks of telemedicine, and a discussion of why a group of quote-unquote blockbuster migraine medicines might struggle on the market. Plus, CNBC biotech reporter Meg Tirrell calls in to debate whether biotech’s Four Horsemen — Celgene, Gilead Sciences, Biogen, and Amgen — have lost their luster in the eyes of the investing world.
For more on what we discuss, here’s a breakdown of the proposed merger; here’s a story about telemedicine; here’s a briefing on the migraine race; and here are some stories about the situations at Biogen and at Amgen.
We’ll be back next Thursday evening — and every Thursday evening — so be sure to sign up on iTunes, Stitcher, Google Play, or wherever you get your podcasts.
And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email firstname.lastname@example.org.